NEDD4L and central nervous system cancer: Another study reported that IGF-1-enhanced miR-513a-5p reduced the sensitivity of glioma cells to temozolomide by targeting the NEDD4L-downregulated Wnt/β catenin pathway (Chen et al., 2019).